Stifel analyst Derek Archila downgraded AnaptysBio (ANAB) to Hold from Buy as he is less confident etokimab will be meaningfully differentiated from Sanofi (SNY) and Regeneron's (REGN) Dupixent after the latter companies reported results from their Phase 2 study for REGN3500, an antiIL-33 antibody, in asthma. REGN3500 did numerically worse than Dupixent as a monotherapy and the combination of REGN3500/Dupixent did not confer a benefit over Dupixent alone, noted Archila. He lowered his view on the odds of success for etokimab to 50% from 55% and also cut his market share assumptions following the competitors' data. Archila cut his price target on AnaptysBio shares to $74 from $124.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here